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The statistics pertaining to heart failure are awesome. It
now affects 4.6 million Americans, and 400,000 new cases
are diagnosed each year. After a diagnosis is made, less than
50% of patients survive more than five years, and less than
25% survive more than 10 years. Class IV heart failure
carries about a 50% mortality in one year. Deaths from heart
failure rose 120% from 1979 to 1996, and hospital dis-
charges rose from 377,000 to 870,000. Heart failure is the
number one hospital DRG in the Medicare population.
This epidemic of heart failure has spawned a new
organization, the Heart Failure Society of America. They
have designated February 14–21 as Heart Failure Aware-
ness Week. Part of the reason for this is to highlight relative
inequities of NIH funding for heart failure research. For
example, in 1997 the NIH allocated $28 million for breast
cancer research and $132 million for lung cancer research.
Yet the prevalence of heart failure is double that of the other
two diseases combined.
There are three main goals of this heart failure initiative:
1. Enhance the public’s recognition of heart failure as a
defined cardiac disease of epidemic proportions.
2. Educate the public that a diagnosis of heart failure is not
a death sentence.
3. Educate the public that with early recognition, appro-
priate therapy, and careful emphasis on the salient
aspects of diet, exercise, and medical care, patients can
lead productive lives.
The last two decades of the twentieth century included a
remarkable number of pharmaceutical trials involving pa-
tients with heart failure. We learned that positive inotropic
agents increase mortality, although digoxin was mortality-
neutral. Angiotensin-converting enzyme (ACE) inhibitor
trials were remarkably uniform in decreasing morbidity and
mortality and slowing down remodeling. It is surprising that
spironolactone reduced mortality in class IV patients who
were already receiving the standard triple therapy of digoxin,
diuretics, and ACE inhibitors. Beta blockers reduced mor-
tality in class II and class III patients. Thus, there is now
standard quadruple therapy in at least some subsets of
patients. The angiotensin receptor blockers emerged as a
major drug class in patients with heart failure. The neuro-
hormonal hypothesis of heart failure was validated, and a
number of new antagonists are being tested. Despite these
advances, sudden death, the mode of death in about half of
heart failure patients, remains a challenge.
Diastolic heart failure has emerged as a common disorder,
especially in older patients. Such patients remain a challenge
to the clinician because we have scant trial data on how best
to treat them. A complete understanding of the causes of
dilated cardiomyopathy also remains an elusive goal. These
are only a few of the challenges facing us in this new
century. In any event, this common disorder will command
more of our attention in the future and certainly justifies the
designation of a week as Heart Failure Awareness Week.
The odds are good that each of us will be treating several
such patients during that very week.
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